Foundry Gross Profitability Industry-Neutral Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1NVDA | NVIDIA CORP | Technology | $4.91T | 34.25% |
2AAPL | APPLE INC | Technology | $4.90T | 34.20% |
3LLY | ELI LILLY & CO | Healthcare | $1.11T | 7.75% |
4MU | MICRON TECHNOLOGY INC | Technology | $958.80B | 6.69% |
5LRCX | LAM RESEARCH CORP | Technology | $391.80B | 2.73% |
6APP | APPLOVIN CORP | Technology | $142.62B | 1.00% |
7SCCO | SOUTHERN COPPER CORP | Basic Materials | $142.48B | 0.99% |
8BKNG | BOOKING HOLDINGS INC | Industrials | $140.78B | 0.98% |
9SBUX | STARBUCKS CORP | Consumer Cyclical | $120.23B | 0.84% |
10FTNT | FORTINET INC | Technology | $118.40B | 0.83% |
11ADBE | ADOBE INC | Technology | $94.31B | 0.66% |
12FDX | FEDEX CORP | Industrials | $74.68B | 0.52% |
13CL | COLGATE PALMOLIVE CO | Consumer Defensive | $74.40B | 0.52% |
14GWW | WW GRAINGER INC | Industrials | $65.86B | 0.46% |
15ODFL | OLD DOMINION FREIGHT LINE INC | Industrials | $48.63B | 0.34% |
16IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 0.31% |
17NTRA | NATERA INC | Healthcare | $38.87B | 0.27% |
18ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.25% |
19ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.24% |
20UI | UBIQUITI INC | Technology | $33.04B | 0.23% |
21ZTS | ZOETIS INC | Healthcare | $32.10B | 0.22% |
22FICO | FAIR ISAAC CORP | Technology | $29.15B | 0.20% |
23TPR | TAPESTRY INC | Consumer Cyclical | $28.58B | 0.20% |
24JBHT | HUNT J B TRANSPORT SERVICES INC | Industrials | $27.48B | 0.19% |
25MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $26.47B | 0.18% |
26VRSN | VERISIGN INC | Technology | $25.27B | 0.18% |
27XPO | XPO INC | Industrials | $25.25B | 0.18% |
28EXPD | EXPEDITORS INTERNATIONAL OF WASHINGTON INC | Industrials | $23.91B | 0.17% |
29TEAM | ATLASSIAN CORP | Technology | $23.67B | 0.17% |
30LUV | SOUTHWEST AIRLINES CO | Industrials | $23.50B | 0.16% |
31INCY | INCYTE CORP | Healthcare | $23.42B | 0.16% |
32P | EVERPURE INC | Technology | $23.06B | 0.16% |
33ROKU | ROKU INC | Communication Services | $21.32B | 0.15% |
34NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.12% |
35THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 0.12% |
36NTNX | NUTANIX INC | Technology | $14.89B | 0.10% |
37EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.10% |
38PINS | PINTEREST INC | Communication Services | $13.00B | 0.09% |
39MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $12.76B | 0.09% |
40DKNG | DRAFTKINGS INC | Consumer Cyclical | $12.37B | 0.09% |
41IESC | IES HOLDINGS INC | Industrials | $12.21B | 0.09% |
42AXSM | AXSOME THERAPEUTICS INC | Healthcare | $11.84B | 0.08% |
43W | WAYFAIR INC | Consumer Cyclical | $11.79B | 0.08% |
44SAIA | SAIA INC | Industrials | $11.65B | 0.08% |
45HUBS | HUBSPOT INC | Technology | $11.49B | 0.08% |
46PODD | INSULET CORP | Healthcare | $11.36B | 0.08% |
47CART | INSTACART (MAPLEBEAR INC) | Consumer Cyclical | $10.77B | 0.08% |
48DPZ | DOMINOS PIZZA INC | Consumer Cyclical | $10.72B | 0.07% |
49AYI | ACUITY INC (DE) | Industrials | $9.99B | 0.07% |
50CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.07% |
51MANH | MANHATTAN ASSOCIATES INC | Technology | $9.66B | 0.07% |
52HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.06% |
53CHWY | CHEWY INC | Consumer Cyclical | $8.57B | 0.06% |
54ETSY | ETSY INC | Consumer Cyclical | $7.98B | 0.06% |
55HIMS | HIMS & HERS HEALTH INC | Consumer Defensive | $7.60B | 0.05% |
56RSI | RUSH STREET INTERACTIVE INC | Consumer Cyclical | $7.56B | 0.05% |
57ACI | ALBERTSONS COMPANIES INC | Consumer Defensive | $7.47B | 0.05% |
58RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.31B | 0.05% |
59MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $7.25B | 0.05% |
60LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.05% |
61MSM | MSC INDUSTRIAL DIRECT CO INC | Industrials | $6.97B | 0.05% |
62HNGE | HINGE HEALTH INC | Healthcare | $6.74B | 0.05% |
63APPF | APPFOLIO INC | Technology | $6.36B | 0.04% |
64SEZL | SEZZLE INC | Financial Services | $5.87B | 0.04% |
65PEGA | PEGASYSTEMS INC | Technology | $5.39B | 0.04% |
66TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.04% |
67RELY | REMITLY GLOBAL INC | Technology | $5.08B | 0.04% |
68PTRN | PATTERN GROUP INC | Consumer Cyclical | $4.97B | 0.03% |
69KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.03% |
70SITE | SITEONE LANDSCAPE SUPPLY INC | Industrials | $4.60B | 0.03% |
71ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.03% |
72RHI | ROBERT HALF INC | Industrials | $4.28B | 0.03% |
73ANF | ABERCROMBIE & FITCH CO | Consumer Cyclical | $4.23B | 0.03% |
74BOX | BOX INC | Technology | $4.22B | 0.03% |
75EXTR | EXTREME NETWORKS INC | Technology | $3.97B | 0.03% |
76WING | WINGSTOP INC | Consumer Cyclical | $3.88B | 0.03% |
77YETI | YETI HOLDINGS INC | Consumer Cyclical | $3.87B | 0.03% |
78CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.03% |
79ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $3.67B | 0.03% |
80NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.02% |
81ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.56B | 0.02% |
82RNG | RINGCENTRAL INC | Technology | $3.46B | 0.02% |
83WDFC | WD 40 CO | Basic Materials | $3.31B | 0.02% |
84WRBY | WARBY PARKER INC | Healthcare | $3.24B | 0.02% |
85CARG | CARGURUS INC | Consumer Cyclical | $3.16B | 0.02% |
86SUPN | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.79B | 0.02% |
87GRND | GRINDR INC | Technology | $2.71B | 0.02% |
88TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.02% |
89CALX | CALIX INC | Technology | $2.50B | 0.02% |
90CMPR | CIMPRESS PLC | Communication Services | $2.49B | 0.02% |
91BLBD | BLUE BIRD CORP | Consumer Cyclical | $2.48B | 0.02% |
92VCEL | VERICEL CORP | Healthcare | $2.38B | 0.02% |
93BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.02% |
94AXGN | AXOGEN INC | Healthcare | $2.12B | 0.01% |
95CDNA | CAREDX INC | Healthcare | $2.05B | 0.01% |
96SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $2.02B | 0.01% |
97ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.01% |
98URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.01% |
99HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.01% |
100APPN | APPIAN CORP | Technology | $1.92B | 0.01% |
101SAM | BOSTON BEER CO INC | Consumer Defensive | $1.86B | 0.01% |
102NVCR | NOVOCURE LTD | Healthcare | $1.84B | 0.01% |
103SONO | SONOS INC | Technology | $1.80B | 0.01% |
104FLO | FLOWERS FOODS INC | Consumer Defensive | $1.80B | 0.01% |
105ASAN | ASANA INC | Technology | $1.77B | 0.01% |
106ATRC | ATRICURE INC | Healthcare | $1.77B | 0.01% |
107HROW | HARROW INC | Healthcare | $1.74B | 0.01% |
108TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.01% |
109ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.01% |
110IDT | IDT CORP | Communication Services | $1.57B | 0.01% |
111XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.01% |
112INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.01% |
113YELP | YELP INC | Communication Services | $1.44B | 0.01% |
114AIP | ARTERIS INC | Technology | $1.43B | 0.01% |
115BJRI | BJS RESTAURANTS INC | Consumer Cyclical | $1.42B | 0.01% |
116BRBR | BELLRING BRANDS INC | Consumer Defensive | $1.41B | 0.01% |
117OMDA | OMADA HEALTH INC | Healthcare | $1.41B | 0.01% |
118WINA | WINMARK CORP | Consumer Cyclical | $1.39B | 0.01% |
119LINC | LINCOLN EDUCATIONAL SERVICES CORP | Consumer Defensive | $1.36B | 0.01% |
120REAL | THEREALREAL INC | Consumer Cyclical | $1.35B | 0.01% |
121NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.01% |
122LZ | LEGALZOOMCOM INC | Industrials | $1.33B | 0.01% |
123GIC | GLOBAL INDUSTRIAL CO | Industrials | $1.32B | 0.01% |
124DMLP | DORCHESTER MINERALS LP | Energy | $1.31B | 0.01% |
125ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.31B | 0.01% |
126UPBD | UPBOUND GROUP INC | Technology | $1.29B | 0.01% |
127NSSC | NAPCO SECURITY TECHNOLOGIES INC | Industrials | $1.29B | 0.01% |
128ARDX | ARDELYX INC | Healthcare | $1.28B | 0.01% |
129HLF | HERBALIFE LTD | Consumer Defensive | $1.24B | 0.01% |
130CBRL | CRACKER BARREL OLD COUNTRY STORE INC | Consumer Cyclical | $1.20B | 0.01% |
131XPEL | XPEL INC | Consumer Cyclical | $1.19B | 0.01% |
132ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.01% |
133PXED | PHOENIX EDUCATION PARTNERS INC | Consumer Defensive | $1.09B | 0.01% |
134GRPN | GROUPON INC | Communication Services | $1.06B | 0.01% |
135KFRC | KFORCE INC | Industrials | $1.04B | 0.01% |
136PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.01% |
137APEI | AMERICAN PUBLIC EDUCATION INC | Consumer Defensive | $930M | 0.01% |
138EVER | EVERQUOTE INC | Communication Services | $925M | 0.01% |
139RDVT | RED VIOLET INC | Technology | $920M | 0.01% |
140TALK | TALKSPACE INC | Healthcare | $873M | 0.01% |
141PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.01% |
142TDUP | THREDUP INC | Consumer Cyclical | $852M | 0.01% |
143SIBN | SI-BONE INC | Healthcare | $771M | 0.01% |
144KRT | KARAT PACKAGING INC | Consumer Cyclical | $760M | 0.01% |
145DSP | VIANT TECHNOLOGY INC | Technology | $754M | 0.01% |
146RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.01% |
147MAMA | MAMA'S CREATIONS INC | Consumer Defensive | $700M | 0.00% |
148TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.00% |
149NRDS | NERDWALLET INC | Communication Services | $609M | 0.00% |
150GYRE | GYRE THERAPEUTICS INC | Healthcare | $587M | 0.00% |
151MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.00% |
152VITL | VITAL FARMS INC | Consumer Defensive | $581M | 0.00% |
153WEAV | WEAVE COMMUNICATIONS INC | Healthcare | $575M | 0.00% |
154OOMA | OOMA INC | Communication Services | $568M | 0.00% |
155ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.00% |
156NPCE | NEUROPACE INC | Healthcare | $548M | 0.00% |
157SPT | SPROUT SOCIAL INC | Technology | $518M | 0.00% |
158LWAY | LIFEWAY FOODS INC | Consumer Defensive | $488M | 0.00% |
159OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.00% |
160VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.00% |
161DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.00% |
162PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.00% |
163BBW | BUILD-A-BEAR WORKSHOP INC | Consumer Cyclical | $428M | 0.00% |
164QMCO | QUANTUM CORP | Technology | $419M | 0.00% |
165USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $403M | 0.00% |
166NATH | NATHANS FAMOUS INC | Consumer Cyclical | $393M | 0.00% |
167EOLS | EVOLUS INC | Healthcare | $377M | 0.00% |
168FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $365M | 0.00% |
169NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $359M | 0.00% |
170ELMD | ELECTROMED INC | Healthcare | $349M | 0.00% |
171XPOF | XPONENTIAL FITNESS INC | Consumer Cyclical | $328M | 0.00% |
172VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.00% |
173BKKT | BAKKT INC | Technology | $323M | 0.00% |
174MKTW | MARKETWISE INC | Technology | $314M | 0.00% |
175BKTI | BK TECHNOLOGIES CORP | Technology | $307M | 0.00% |
176OFLX | OMEGA FLEX INC | Industrials | $302M | 0.00% |
177UCFI | CN HEALTHY FOOD TECH GROUP CORP | Consumer Defensive | $288M | 0.00% |
178SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.00% |
179TBCH | TURTLE BEACH CORP | Technology | $258M | 0.00% |
180QTTB | Q32 BIO INC | Healthcare | $255M | 0.00% |
181NUS | NU SKIN ENTERPRISES INC | Consumer Defensive | $254M | 0.00% |
182CXDO | CREXENDO INC | Communication Services | $248M | 0.00% |
183JILL | JJILL INC | Consumer Cyclical | $248M | 0.00% |
184SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.00% |
185FC | FRANKLIN COVEY CO | Industrials | $229M | 0.00% |
186SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.00% |
187KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.00% |
188AGEN | AGENUS INC | Healthcare | $209M | 0.00% |
189BDSX | BIODESIX INC | Healthcare | $204M | 0.00% |
190DERM | JOURNEY MEDICAL CORP | Healthcare | $197M | 0.00% |
191INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.00% |
192MRDN | MERIDIAN HOLDINGS INC | Communication Services | $171M | 0.00% |
193OWLT | OWLET INC | Healthcare | $162M | 0.00% |
194RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.00% |
195OCC | OPTICAL CABLE CORP | Technology | $130M | 0.00% |
196CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.00% |
197INSG | INSEEGO CORP | Technology | $122M | 0.00% |
198AKA | AKA BRANDS HOLDING CORP | Consumer Cyclical | $119M | 0.00% |
199MED | MEDIFAST INC | Consumer Cyclical | $114M | 0.00% |
200TZOO | TRAVELZOO | Communication Services | $113M | 0.00% |
201CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $103M | 0.00% |
202VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.00% |
203SOTK | SONO TEK CORP | Technology | $86M | 0.00% |
204CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
205AEYE | AUDIOEYE INC | Technology | $82M | 0.00% |
206BARK | BARK INC | Consumer Cyclical | $82M | 0.00% |
207LFVN | LIFEVANTAGE CORP | Consumer Defensive | $78M | 0.00% |
208SEAT | VIVID SEATS INC | Communication Services | $78M | 0.00% |
209AIRG | AIRGAIN INC | Technology | $76M | 0.00% |
210ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.00% |
211BODI | BEACHBODY COMPANY INC | Communication Services | $75M | 0.00% |
212WFCF | WHERE FOOD COMES FROM INC | Technology | $63M | 0.00% |
213SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $14.33T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 94% toward Growth. +1% unclassified (27 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 213 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual37.1%Margin-37.9%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual34.2%Margin-9.2%The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual41.2%Margin-16.2%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
At least 50% of total assets must sit in cash, government securities, other RICs, and other securities limited to 5% of assets and 10% of the issuer's voting securities per issuer.
Required>= 50.0%Actual37.1%Margin-12.9%Arithmetically entailed by '40 Act 5(b)(1) diversification (75%/5% asset leg) — it cannot fail independently, so it is reported outside the tally rather than counted as a separate check.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 213 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 17.4% | 31.8% |
| 3 yearsp.a. | 31.6% | 29.1% |
| 5 yearsp.a. | 16.8% | 23.3% |
| 10 yearsp.a. | 14.9% | 12.3% |
| Since inceptionp.a. | 10.5% | 8.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 4.8% | 14.3% |
| 2025 | 25.0% | 25.6% |
| 2024 | 60.4% | 40.7% |
| 2023 | 27.6% | 7.0% |
| 2022 | -22.1% | 14.2% |
| 2021 | 18.3% | 8.9% |
| 2020 | 21.6% | 12.1% |
| 2019 | 26.4% | 6.3% |
| 2018 | -5.0% | 14.1% |
| 2017 | 2.5% | -18.8% |
| 2016 | 8.5% | -4.4% |
| 2015 | 0.9% | 17.5% |
| 2014 | 14.4% | 21.2% |
| 2013 | 34.0% | 5.4% |
| 2012 | 10.6% | 2.7% |
| 2011 | 1.0% | -4.2% |
| 2010 | 22.2% | -0.1% |
| 2009 | 33.7% | -4.0% |
| 2008 | -24.6% | 37.9% |
| 2007 | 4.0% | -3.6% |
| 2006 | 12.0% | 0.8% |
| 2005 | 3.5% | 0.7% |
| 2004 | 23.0% | -1.6% |
| 2003 | 21.0% | -23.0% |
| 2002 | -16.5% | 16.3% |
| 2001 | -15.5% | 7.8% |
| 2000 | 24.0% | 123.2% |
| 1999 | 18.2% | -15.0% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Gross Profitability Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a Gross Profitability signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.